ArticleChemical communications (Cambridge, England)2017
Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89.
Article in Chemical communications (Cambridge, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 49 citations in OpenAlex.
- Precision theranostics in oncology: integrating antibody-drug conjugates, radioimmunotherapy, and immuno‑PET for adaptive cancer care.Discover oncology · 2026Review
- The Evaluation of (1Molecules (Basel, Switzerland) · 2025Article
- From Desferrioxamine B Umpolung to an Enantiopure Bifunctional Chelator forChemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Isopeptidic Desferrioxamine Analogues: The Role of Hydroxamate Spacing for Chelation of ZrChemMedChem · 2025Article
- Bifunctional octadentate pseudopeptides as Zirconium-89 chelators for immuno-PET applications.EJNMMI radiopharmacy and chemistry · 2024Article
- Macrophage PET imaging in mouse models of cardiovascular disease and cancer with an apolipoprotein-inspired radiotracer.Npj imaging · 2024Article
- Click-to-Release: Cleavable Radioimmunoimaging with [Theranostics · 2023Article
- The Race for Hydroxamate-Based Zirconium-89 Chelators.Cancers · 2021Review
- Developing theNature chemistry · 2021Article
- Polyazamacrocycle Ligands FacilitateInorganic chemistry · 2020Article
- A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89.Inorganic chemistry · 2020Article
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* forEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Ultra-selective ligand-driven separation of strategic actinides.Nature communications · 2019Article
- Progress of Coordination and Utilization of Zirconium-89 for Positron Emission Tomography (PET) Studies.Nuclear medicine and molecular imaging · 2019Review
- A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevantDalton transactions (Cambridge, England : 2003) · 2018Article
- Recent Advances in Zirconium-89 Chelator Development.Molecules (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 3 countries.
Funding
Abstract
The future of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.